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Effect of changes in inspired 
oxygen fraction on oxygen delivery 
during cardiac surgery: a substudy 
of the CARROT trial
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When hemoglobin (Hb) is fully saturated with oxygen, the additional gain in oxygen delivery 
 (DO2) achieved by increasing the fraction of inspired oxygen  (FiO2) is often considered clinically 
insignificant. In this study, we evaluated the change in  DO2, interrogated by mixed venous oxygen 
saturation  (SvO2), in response to a change in  FiO2 of 0.5 during cardiac surgery. When patients were 
hemodynamically stable,  FiO2 was alternated between 0.5 and 1.0 in on‑pump cardiac surgery 
patients (pilot study), and between 0.3 and 0.8 in off‑pump coronary artery bypass grafting patients 
(substudy of the CARROT trial). After the patient had stabilized, a blood gas analysis was performed to 
measure  SvO2. The observed change in  SvO2 (ΔSvO2) was compared to the expected ΔSvO2 calculated 
using Fick’s equation. A total 106 changes in  FiO2 (two changes per patient; total 53 patients; 
on‑pump, n = 36; off‑pump, n = 17) were finally analyzed. While Hb saturation remained near 100% 
(on‑pump, 100%; off‑pump, mean [SD] = 98.1% [1.5] when  FiO2 was 0.3 and 99.9% [0.2] when  FiO2 
was 0.8),  SvO2 changed significantly as  FiO2 was changed (the first and second changes in on‑pump, 
7.7%p [3.8] and 7.6%p [3.5], respectively; off‑pump, 7.9%p [4.9] and 6.2%p [3.9]; all P < 0.001). As a 
total, regardless of the surgery type, the observed ΔSvO2 after the  FiO2 change of 0.5 was ≥ 5%p in 82 
(77.4%) changes and ≥ 10%p in 31 (29.2%) changes (mean [SD], 7.5%p [3.9]). Hb concentration was 
not correlated with the observed ΔSvO2 (the first changes, r =  − 0.06, P = 0.677; the second changes, 
r =  − 0.21, P = 0.138). The mean (SD) residual ΔSvO2 (observed − expected ΔSvO2) was 0%p (4). Residual 
ΔSvO2 was more than 5%p in 14 (13.2%) changes and exceeded 10%p in 2 (1.9%) changes. Residual 
ΔSvO2 was greater in patients with chronic kidney disease than in those without (median [IQR], 5%p 
[0 to 7] vs. 0%p [− 3 to 2]; P = 0.049).  DO2, interrogated by  SvO2, may increase to a clinically significant 
degree as  FiO2 is increased during cardiac surgery, and the increase of  SvO2 is not related to Hb 
concentration.  SvO2 increases more than expected in patients with chronic kidney disease. Increasing 
 FiO2 can be used to increase  DO2 during cardiac surgery.
The ultimate goal of hemodynamic management is to optimize oxygen transport and maintain adequate tissue 
oxygenation. Shoemaker et al. demonstrated in their early study that reduced oxygen transport was a predictor 
of death after major surgery for life-threatening  shock1. The concept of oxygen transport optimization evolved 
following that study, and has become an important component of goal-directed hemodynamic  management2.
Convective oxygen transport describes oxygen delivery  (DO2) to peripheral tissues and organs via the circula-
tion system, which can be managed by monitoring mixed venous oxygen saturation  (SvO2)3,4.  DO2 is a product of 
cardiac output (CO) and arterial oxygen content  (CaO2)3,4, and  CaO2 is a function of hemoglobin (Hb), arterial 
oxygen saturation  (SaO2), and arterial oxygen partial pressure  (PaO2), described as  follows5:
CaO2 = (k1 ×Hb× SaO2)+ (k2 × PaO2)
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where k1 (Hüfner’s constant) and k2 (Bunsen’s coefficient) are approximately 1.34 ml/g and 0.0034 ml/dl/mmHg, 
respectively. As can be inferred from this equation, the theoretical contribution of  PaO2 to  DO2 is negligible 
compared to the Hb  concentration3,6. Consequently, it is a generally accepted idea that an increase in  DO2 
that can be achieved by increasing the fraction of inspired oxygen  (FiO2) is minimal after Hb is saturated. This 
concept can lead physicians to overlook the importance of  FiO2 adjustment in perioperative  DO2 management.
Therefore, based on our clinical experience, we hypothesized that a significant increase in  DO2 could be 
achieved by increasing  FiO2 (and  PaO2), even after Hb is fully saturated in cardiac surgery patients. To evalu-
ate this hypothesis, we analyzed the effect of changing  FiO2 on  DO2 reflected as  SvO2 in patients undergoing 
cardiac surgery.
Results
The study flow chart is presented in Fig. 1. Among the on-pump cardiac surgery patients (n = 40) enrolled in 
protocol 1 (see the “Methods” section), four dropped out because the blood gas results were missing (n = 2), 
rewarming was started during the study (n = 1) or red blood cells were transfused during the study (n = 1) 
(Fig. Methods1a). None of the participants (n = 17) of the CARROT trial who underwent off-pump coronary 
artery bypass grafting (OPCAB) dropped out from protocol 2 (Fig. 1b; see the “” section). Missing values were 
omitted without data imputation. The remaining 53 patients (on-pump, n = 36; OPCAB, n = 17) were included 
in the final analysis (Fig. 1).
The patient characteristics are described in Table 1. The mean (SD) Hb concentration was 7.7 g/dl (1.3), and 
the mean nasopharyngeal temperature was 29.2 °C (1.5), in on-pump patients following protocol 1. The mean 
Hb concentration and the nasopharyngeal temperature were 11.5 g/dl (2.1) and 35.8 °C (0.6), respectively in 
OPCAB patients following protocol 2. The mean cardiopulmonary bypass (CPB) flow rate was 4.1 l/min (0.5) 
in on-pump patients, and the mean CO measured via a pulmonary artery catheter using the thermodilution 
method was 3.3 l/min (0.5) in OPCAB patients. The hemodynamic variables measured at T0–T2 throughout 
the study are presented in Supplementary Table S1 online.
Figure 1.  Study flow chart of (a) on-pump and (b) off-pump patients.  FiO2, fraction of inspired oxygen.
3
Vol.:(0123456789)
Scientific Reports |        (2021) 11:17862  | https://doi.org/10.1038/s41598-021-97555-2
www.nature.com/scientificreports/
Comparison of  SvO2 levels measured at different  FiO2 levels. SaO2 remained relatively constant 
during both protocols.  SaO2 was 100% in all on-pump cardiac surgery patients at every  FiO2 level. In OPCAB 
patients, the mean (SD)  SaO2 was 98.1% (1.5) when  FiO2 was 0.3 and 99.9% (0.2) when  FiO2 was 0.8. The pat-
tern of  PaO2 change in response to the change of  FiO2 in every patient is shown in Fig. 2 and Supplementary 
Table S1 online.
The changes in  SvO2 throughout the study period are shown in Fig. 3.  SvO2 changed significantly with the 
change of  FiO2 (and  PaO2) in on-pump cardiac surgery patients (mean [SD], T0–T1 7.7%p [3.8] and T1–T2 
7.6%p [3.5]; both P < 0.001) and OPCAB patients (T0–T1 7.9%p [4.9] and T1–T2 6.2%p [3.9]; both P < 0.001). 
Regardless of the surgery type, 82 (77.4%) changes had an observed ΔSvO2 ≥ 5%p and 31 (29.2%) had an observed 
ΔSvO2 ≥ 10%p (mean [SD], 7.5%p [3.9]).
Table 1.  Demographics and baseline characteristics of the study population. Data are presented as mean (SD) 
or number (%). ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, CPB 
cardiopulmonary bypass. *Values measured at T0. † Measured at the nasopharynx. ‡ Based on the pump flow 
rate.
On-pump (n = 36) Off-pump (n = 17)
Age (years) 61.4 (12.4) 65.7 (7.6)
Female 18 (50.0%) 6 (35.3%)
Height (cm) 161.8 (10.9) 161.5 (10.2)
Weight (kg) 63.3 (14.4) 66.4 (8.5)
Comorbidities
Hypertension 11 (30.6%) 12 (70.6%)
Diabetes 5 (13.9%) 11 (64.7%)
Chronic kidney disease 1 (2.8%) 5 (29.4%)
Cerebrovascular disease 5 (13.9%) 1 (5.9%)
Chronic obstructive lung disease 0 (0%) 0 (0%)
Infective endocarditis 1 (2.8%) 0 (0%)
Congestive heart failure 11 (30.6%) 2 (11.8%)
Medication history
ACEi or ARB 9 (25.0%) 7 (41.2%)
Beta blockers 14 (38.9%) 7 (41.2%)
Calcium channel blockers 7 (19.4%) 5 (29.4%)
Diuretics 26 (72.2%) 5 (29.4%)
Statins 13 (36.1%) 23 (63.9%)
Surgery type
Coronary artery bypass grafting 0 (0%) 17 (100%)
Valve 17 (47.2%) NA
Thoracic aorta 2 (5.6%) NA
Valve + Coronary 1 (2.8%) NA
Valve + Thoracic aorta 6 (16.7%) NA
Valve + Maze procedure 7 (19.4%) NA
Miscellaneous 3 (8.3%) NA
Surgical profiles
Redo surgery 6 (16.7%) 0 (0%)
Surgery duration (min) 327 (71) 362 (44)
CPB duration (min) 163 (53) NA
Laboratory data
Ejection fraction (%) 57 (10) 53 (13)
Serum creatinine (mg/dl) 0.8 (0.2) 1.4 (1.9)
Glomerular filtration rate (ml/min/1.73  m2) 86 (18) 76 (26)
Hemoglobin (g/dl)* 7.7 (1.3) 11.5 (2.1)
Hemodynamic data*
Core body temperature (°C)† 29.2 (1.5) 35.8 (0.6)
Mean blood pressure (mmHg) 62 (6) 75 (13)
Cardiac output (l/min) 4.1 (0.5)‡ 3.3 (0.5)
Cardiac index (l/min/m2) 2.5 (0.2)‡ 1.9 (0.2)
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ΔSvO2 according to Hb concentration. The relationship between Hb concentration and ΔSvO2 is shown 
in Fig. 4. The Hb concentration (within the range 5.1–15.3 g/dl) was not correlated with the observed ΔSvO2 
(T0–T1, r =  − 0.06, P = 0.677; T1–T2, r =  − 0.21, P = 0.138).
Comparison of the observed and expected ΔSvO2. The Bland–Altman plot for the observed and 
expected ΔSvO2 is presented in Fig. 5. Overall,  SvO2 changed following a change in  FiO2. The maximum residual 
ΔSvO2 (observed − expected ΔSvO2) was 12%p, and the mean (SD) residual ΔSvO2 was 0%p (4). Residual ΔSvO2 
was more than 5%p in 14 (13.2%) changes. Residual ΔSvO2 exceeded 10%p in two changes.
Figure 2.  Change of  PaO2 according to that of fraction of inspired oxygen in (a) on-pump and (b) off-pump 
patients.  PaO2, arterial oxygen partial pressure. Created with R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria; https:// www.R- proje ct. org/.
Figure 3.  Change of  SvO2 according to different  FiO2 levels in (a) on-pump and (b) off-pump patients. 
 SvO2, mixed venous oxygen saturation;  FiO2, fraction of inspired oxygen. Created with R: A language and 
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Exploratory analysis of factors associated with residual  SvO2. A forest plot summarizing resid-
ual ΔSvO2 according to preoperative comorbidities is presented in Fig. 6. Patients with chronic kidney disease 
(n = 6) had significantly greater residual ΔSvO2 than those without chronic kidney disease (n = 47) (median 
[IQR], 5%p [0 to 7] vs. 0%p [− 3 to 2]; P = 0.049) (Fig. 6). However, no significant difference was observed in 
residual ΔSvO2 between patients with and without diabetes (n = 16 and 37, respectively; mean [SD], 2%p [5] 
vs. − 1%p [4]; P = 0.104), or between those with and without hypertension (n = 23 and 30, respectively; 0%p [5] 
vs. 0%p [4]; P = 0.933). Residual ΔSvO2 also did not differ according to whether patients had cerebrovascular 
disease or not (n = 6 and 47, respectively; median [IQR], − 1%p [− 1 to 1] vs. 0%p [− 4 to 3]; P = 0.967), or whether 
they had congestive heart failure or not (n = 13 and 40, respectively; mean [SD], 1%p [4] vs. 0%p [5]; P = 0.544).
The change of Hb equivalent that increases  DO2 to the same extent as ΔFiO2 of 0.5. The 
median (IQR) ΔHb equivalent that increases  DO2 to the same extent as ΔFiO2 of 0.5 was 0.7 (0.6–0.8) g/dl. The 
maximum value was 1.1 g/dl. The distribution of the ΔHb equivalent values is presented as a histogram in Fig. 7. 
In more than 90% of changes with a change of  FiO2, ΔFiO2 of 0.5 was equivalent to an ΔHb of more than 0.5 g/
dl (97 changes, 91.5%), suggesting that use of a higher  FiO2, at least temporarily, can achieve a similar effect as 
transfusion in terms of  DO2.
Figure 4.  The relationship between ΔSvO2 and hemoglobin concentration. ΔSvO2, change of mixed venous 
oxygen saturation. Red dots, T0–T1; blue dots, T1–T2. Created with R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria; https:// www.R- proje ct. org/.
Figure 5.  Bland–Altman plot for the observed versus the expected ΔSvO2. Dashed lines indicate the limits of 
agreement (the mean ± 1.96 × the standard deviation of the residual ΔSvO2). ΔSvO2, change of mixed venous 
oxygen saturation. Red points, T0–T1; blue points, T1–T2. Created with R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria; https:// www.R- proje ct. org/.
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:17862  | https://doi.org/10.1038/s41598-021-97555-2
www.nature.com/scientificreports/
Discussion
In this study,  SvO2 increased by ≥ 5%p in more than three-quarters of  FiO2 changes where  FiO2 was increased 
from 0.3 to 0.8 or 0.5 to 1.0 during cardiac surgery, and by ≥ 10%p in more than one-quarter of  FiO2 changes. 
While Hb remained almost fully saturated,  PaO2 changed remarkably as  FiO2 was changed. There was no signifi-
cant association between Hb concentration and ΔSvO2. These results indicate that  DO2 can increase significantly 
following an increase in  PaO2 induced by raising  FiO2 during cardiac surgery. The median ΔHb equivalent to 
the  FiO2 change of 0.5, in terms of its ability to increase  DO2, was 0.7 g/dl. In addition,  SvO2 tended to increase 
beyond the expected value that was calculated using the Fick’s equation, in patients with chronic kidney disease.
Figure 6.  Comparison of the residual ΔSvO2 according to comorbidities. Asterisks refer to non-parametric 
results. Points indicate the mean or the median, lines 95% confidence interval or interquartile range. ΔSvO2, 
change of mixed venous oxygen saturation. R Foundation for Statistical Computing, Vienna, Austria; https:// 
www.R- proje ct. org/.
Figure 7.  Distribution of the ΔHb equivalent that increases oxygen delivery to the same extent as ΔFiO2 of 
0.5. ΔHb, change of hemoglobin concentration. Created with R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria; https:// www.R- proje ct. org/.
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In most patients undergoing cardiac surgery,  SaO2 is maintained at nearly 100% due to supplemental oxygen 
therapy, unless there is a significant shunt or pulmonary morbidity. In our study,  SaO2 was 100% at every  FiO2 
level during on-pump cardiac surgery, and more than 98% and 99% at the  FiO2 levels of 0.3 and 0.8, respectively, 
during OPCAB. In such a situation, it is generally expected that the contribution of  PaO2 to  DO2 will be much 
smaller than that of Hb-bound  oxygen3,6; thus, manipulating  FiO2 would have very little influence on  SvO2 (or 
 DO2)5. Therefore, clinicians may focus only on Hb concentration and transfusion when optimizing  DO2.
Several studies have shown that perioperative  DO2 management is associated with complications after cardiac 
surgery, such as neurologic  injury8–11 and renal  dysfunction12–14. However, previous studies mostly evaluated the 
effect of CO and Hb concentration rather than  FiO28,9,13. Hogue et al. reported that atrial fibrillation accompanied 
by low CO had a significant effect on the likelihood of postoperative  stroke8. Bahrainwala et al. explained the 
link between reduced  DO2 and postoperative stroke in terms of a decrease of Hb concentration  alone9. Ranucci 
et al. also showed that severe hemodilution during CPB increases the risk of renal dysfunction, but emphasized 
that this can be attenuated by increasing  DO2 with raising CO (pump flow)13.
Early studies by Clowes et al.15 and Shoemaker et al.1 revealed that survivors of peritonitis and shock have 
consistently higher  DO2 and oxygen consumption  (VO2) than those who died. Although our study showed that 
higher  FiO2 significantly elevates  DO2, this does not necessarily mean that the use of high  FiO2 would improve 
clinical outcomes: there are several issues that need to be addressed. First, there is growing concern about the 
harmful effects of hyperoxia caused by high  FiO2, although most previous clinical studies failed to demonstrate 
significantly poorer clinical outcomes due to hyperoxia or high  FiO216,17. Second,  DO2 can increase in response 
to transfusion or intravascular volume expansion, but we do not know whether achieving the same level of  SvO2 
with different modalities results in an equivalent distribution of oxygen to the organs; the distribution of oxygen 
supply and demand differs among  organs18. Weinrich et al. failed to find a correlation between surgical site oxygen 
saturation and central venous oxygen saturation in patients undergoing major non-cardiac  surgery19. Similar 
findings have been reported in patients undergoing CPB cardiac surgery, where a significant difference between 
 SvO2 and venous oxygen saturation measured at the brain or gut was  demonstrated20,21. This heterogeneity not 
only exists at the global level, but also at the regional level within an  organ22. However, these are poorly investi-
gated topics, so further studies on are necessary. Currently, there is no firm consensus or established guidelines 
regarding the optimal oxygen therapy for patients undergoing cardiac surgery, and the present study did not 
answer this question. We are conducting a multicenter, cluster-randomized trial (the CARROT trial; Clinicaltri-
als.gov, NCT03945565) to compare the effects of different levels of intraoperative  FiO2 (0.3 vs. 0.8) on clinical 
outcomes after OPCAB, including the length of postoperative hospital stay and major organ injuries.
Recent large-scale randomized trials, such as the TRICS  III23 and the  TITRe224, failed to demonstrate a differ-
ence between restrictive and liberal transfusion strategies in terms of composite adverse outcomes after cardiac 
surgery. In these trials, only Hb concentration was tested as a trigger for red blood cell  transfusion23–25. However, 
from the present study, and our previous  study26 it can be inferred that there may be unknown interactions or 
confounders that make interpretation of the effect of transfusion on outcomes more complex. Although estab-
lishing the Hb threshold is currently the highest priority for transfusion and  DO2 optimization, oxygen therapy 
and plasma dissolved oxygen should also be considered.
The present study had several limitations. First, only a small number of patients were included without an a 
priori sample size calculation. Furthermore, two heterogeneous groups of patients (on- and off-pump cardiac 
surgery patients) with different hemodynamic statuses and comorbidities were enrolled. The levels of  FiO2 also 
differed between the study protocols. Moreover, we only assessed the immediate effect of a change in  FiO2 on 
 SvO2, and did not evaluate whether increasing  SvO2 using a higher  FiO2 ameliorates oxygenation of vital organs 
(which would improve clinical outcomes). We expect that the CARROT trial will answer these questions. Sec-
ond, several (important) variables, such as CO, Hb concentration, and  VO2, were assumed to be constant during 
the  FiO2 changes for this analysis, which was inevitable for the calculation of expected ΔSvO2. To minimize the 
influence of these values, the both protocols were conducted when it was considered the most hemodynamically 
stable with the least surgical manipulation (see the “Methods” section). Obviously, changes in these variables 
were minimal during the study period (Supplementary Table S1 online), but may have affected the observed and 
expected ΔSvO2 values to a certain extent. Third, we only included cardiac surgery patients in this study. Thus, 
our results may not be applicable to patients in other settings, such as non-cardiac surgery patients and non-
surgical, critically ill patients. Fourth, this study did not uncover the mechanism, or assess the clinical impact, 
of the phenomenon whereby a change in  SvO2 caused by a change in  FiO2 was larger than expected in patients 
with chronic kidney disease.
In conclusion,  DO2, interrogated by  SvO2, may be significantly elevated by increasing  FiO2 during cardiac 
surgery. Increasing  FiO2 may be considered when an increase in  DO2 is necessary during cardiac surgery. How-
ever, considering the potential risk of hyperoxia, further studies evaluating the clinical effect of this practice are 
necessary.
Methods
Study population. This study was comprised of on-pump cardiac surgery and OPCAB parts. The part 
involving patients undergoing CPB cardiac surgery was a pilot study, which was approved by the Institutional 
Review Board of Seoul National University Hospital (IRB no., 1909-145-1067) and registered at ClinicalTrials.
gov (NCT04144205). The other part, for patients undergoing OPCAB, was a substudy of the CARROT trial (IRB 
no., 1902-021-1008; ClinicalTrials.gov, NCT03945565).
The present study was performed in compliance with the guidelines for Good Clinical Practice and the Dec-
laration of Helsinki. All participants recruited to this study provided written informed consent.
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Protocol 1: on‑pump cardiac surgery. This part of the study was a pilot study for a future multicenter, 
randomized trial. Forty patients who presented for elective CBP cardiac surgery between November 4, 2019 and 
February 11, 2020 were enrolled in this study. There was no a priori sample size calculation. The exclusion cri-
teria were preoperative supplemental oxygen at a dose equivalent to  FiO2 of > 0.5, symptomatic cerebrovascular 
disease, and > 50% cerebral artery stenosis.
After CPB was initiated, the ascending aorta was cross-clamped and a cardioplegic solution was infused. 
Body temperature was measured at the nasopharynx and bladder, and was lowered to 28–32 °C. The α-stat 
strategy was applied for the pH management during CPB.  FiO2 is initially set to 0.6 on the CBP oxygenator as 
a routine practice at our institution. After asystole was obtained and body temperature had stabilized,  FiO2 was 
sequentially changed from 0.5 to 1.0, and back to 0.5, in the first half of the patients enrolled, and from 1.0 to 
0.5, and back to 1.0, in the other half. Following a 5- to 10-min equilibration period for the three sequential 
 FiO2 levels (T0–T2, respectively), blood gas analysis was performed using arterial and mixed venous blood 
sampled from the radial artery and venous reservoir of the CPB machine, respectively. A point-of-care analyzer 
(Gem®Premier™3000; Instrumentation Laboratory, Bedford, MA, USA) was utilized for the blood gas analysis. 
The pump flow rate of the CPB machine was recorded as the CO. Heart rate and mean blood pressure were also 
measured during the  FiO2 changes.
Protocol 2: off‑pump coronary artery bypass grafting. This part of the study was a substudy of the 
CARROT trial, in which elective OPCAB patients were cluster-randomized on a monthly basis to receive  FiO2 
of either 0.3 or 0.8 during surgery. The length of postoperative hospital stay was the primary endpoint; other 
clinical outcomes will be compared in the CARROT trial. All participants taking part in the CARROT trial from 
November 1 to December 31, 2019 were consecutively enrolled in this substudy. Exclusion criteria for the CAR-
ROT trial included robot-assisted surgery, surgery via a thoracotomy, minimally invasive direct coronary artery 
bypass grafting, concomitant major surgery, any pulmonary condition requiring supplemental oxygen through 
any route before surgery, and preoperative use of mechanical circulatory assist devices.
After anesthesia was induced, the patients in the CARROT trial were mechanically ventilated with  FiO2 of 0.3 
or 0.8 during surgery based on the above-described cluster randomization (November 2019,  FiO2 of 0.3; Decem-
ber 2019,  FiO2 of 0.8). A pulmonary artery catheter (Swan-Ganz CCOmbo V 774HF75; Edwards Lifesciences, 
Irvine, CA, USA) was placed and connected to a continuous  SvO2 and CO monitoring device (Vigilance II™; 
Edwards Lifesciences). The substudy protocol was performed during graft harvesting to ensure hemodynamic 
stability and minimal blood loss.  FiO2 was changed from 0.3 to 0.8, and then back to 0.3, in patients allocated 
to receive  FiO2 of 0.3 in the CARROT trial, while in those who received  FiO2 of 0.8 it was changed from 0.8 to 
0.3, and then back to 0.8 (T0–T2, respectively).  FiO2 was held at each level for 5 to 10 min for stabilization, and 
blood gas analysis was performed at T0–T2 on arterial and mixed venous blood obtained from the radial and 
pulmonary arteries, respectively. No intravenous fluids were infused during the study protocol. Nasopharyngeal 
temperature, heart rate, and mean blood pressure were recorded during the  FiO2 changes.
Statistical analysis. The primary endpoint was the observed ΔSvO2 in response to a change in  FiO2. Sec-
ondary endpoint was the difference between the observed and expected ΔSvO2 values (observed − expected 
ΔSvO2), i.e., the residual ΔSvO2.
Forty and 17 patients were recruited for protocol 1 (a pilot study) and protocol 2 (a substudy of the CARROT 
trial), respectively, without a sample size calculation. The statistical analysis was performed as follows. First, the 
observed ΔSvO2 was compared to zero (i.e., no change) using the one-sample t-test in on-pump cardiac and 
OPCAB patients. The observed ΔSvO2 of each patient was calculated as the absolute difference in  SvO2 values 
measured at T0 versus T1, and T1 versus T2, thus giving two ΔSvO2 values per patient: the Bonferroni’s correc-
tion was applied. Second, we explored the distribution of the observed ΔSvO2 according to Hb concentration on 
a scatterplot, regardless of the surgery type. Assuming that the Hb concentration was constant during the change 
of  FiO2 (T0–T2), the Hb concentration measured at T0 was taken as the representative value and used in the 
analysis. Pearson’s correlation analysis was performed to evaluate the association of Hb concentration with the 
observed ΔSvO2. Third, the observed ΔSvO2 was compared to the expected ΔSvO2 using a Bland–Altman plot, 
and the residual ΔSvO2 was calculated. The expected ΔSvO2 was calculated using Fick’s  equation7
where  VO2 is oxygen consumption and  CvO2 is the mixed venous oxygen content. As described earlier,
and similarly,
where  PvO2 is the mixed venous oxygen partial pressure. Therefore,
We assumed that CO and  VO2 remained constant from T0 to T2; hence, the following equation was 
established.
VO2 = CO × (CaO2 − CvO2)
CaO2 = (k1 ×Hb× SaO2)+ (k2 × PaO2)
CvO2 = (k1 ×Hb× SvO2)+ (k2 × PvO2)
VO2 = CO × {(k1 ×Hb× SaO2 + k2 × PaO2)− (k1 ×Hb× SvO2 + k2 × PvO2)}
(k1 ×Hb× SaO2[T0] + k2 × PaO2[T0])− (k1 ×Hb× SvO2[T0]+ k2 × PvO2[T0])
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or
Rearranging this equation, the expected ΔSvO2 (T0–T1 and T1–T2) was calculated as follows:
where ΔSaO2, ΔPaO2, and ΔPvO2 are the absolute difference of the  SaO2,  PaO2, and  PvO2 values measured at 
T0 versus T1, and T1 versus T2. Fourth, an exploratory analysis was performed to identify factors potentially 
associated with the degree of ΔSvO2 according to ΔPaO2. Residual ΔSvO2 was compared among patients with 
and without chronic kidney disease, diabetes, hypertension, cerebrovascular disease, and congestive heart failure 
using the independent t-test or Wilcoxon rank-sum test after checking for normality. Only the residual  SvO2 
calculated at T0 versus T1 was used for this exploratory analysis. Fifth, we exploratively calculated the ΔHb 
equivalent that could increase  DO2 to the same extent as ΔFiO2 of 0.5. For this calculation, it was assumed that 






+ k2 × PaO2[high FiO2]
All statistical analyses and data visualization were performed using R software (version 4.0.0; R Development 
Core Team, Vienna, Austria). Continuous variables are expressed as mean (SD) or median (IQR) as appropriate, 
and categorical variables are expressed as numbers (%). A P-value < 0.05 was considered significant.
Data availability
The data supporting this publication can be accessed by contacting the corresponding authors on reasonable 
request.
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